Last update 23 Jan 2025

Hydrocortisone

Overview

Basic Info

SummaryHydrocortisone, a diminutive yet powerful molecule, is renowned for its aptitude to function as a glucocorticoid receptor (GR) agonist, thereby stimulating the GR. This drug boasts a diverse range of clinical applications and is typically employed in the treatment of a multitude of ailments that are closely associated with adrenal insufficiency, including but not limited to congenital adrenal hyperplasia, adrenal hyperplasia, Addison's disease, and isolated ACTH deficiency. Additionally, it has proven efficacious in treating inflammatory conditions such as subacute thyroiditis, ulcerative colitis, proctocolitis, and ulcerative proctitis. It is worth noting that the FDA initially granted its approval to hydrocortisone on the 5th of August, 1952. The development of hydrocortisone is credited to Merck Sharp & Dohme Corp, which pioneered the drug. Owing to its extraordinary anti-inflammatory and immunosuppressive qualities, hydrocortisone has emerged as a definitive remedy for numerous chronic inflammatory disorders.
Drug Type
Small molecule drug
Synonyms
(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione, 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione, 11beta-hydrocortisone
+ [58]
Target
Mechanism
GR agonists(Glucocorticoid receptor agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (US), Orphan Drug (US), Orphan Drug (EU), Orphan Drug (AU)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H30O5
InChIKeyJYGXADMDTFJGBT-VWUMJDOOSA-N
CAS Registry50-23-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Adrenal Hyperplasia, Congenital
EU
27 May 2021
Adrenal Hyperplasia, Congenital
IS
27 May 2021
Adrenal Hyperplasia, Congenital
LI
27 May 2021
Adrenal Hyperplasia, Congenital
NO
27 May 2021
ACTH Deficiency, Isolated
JP
21 Dec 1972
Adrenal Insufficiency
JP
21 Dec 1972
Infectious Diseases
JP
21 Dec 1972
Thyroiditis, Subacute
JP
21 Dec 1972
Colitis, Ulcerative
US
12 Jan 1966
Proctocolitis
US
12 Jan 1966
Ulcerative proctitis
US
12 Jan 1966
Anaphylaxis
US
15 Dec 1952
Collagen Diseases
US
15 Dec 1952
Edema
US
15 Dec 1952
Eye Diseases
US
15 Dec 1952
Gastrointestinal Diseases
US
15 Dec 1952
Hematologic Diseases
US
15 Dec 1952
Neoplasms
US
15 Dec 1952
Respiratory Diseases
US
15 Dec 1952
Rheumatic Diseases
US
15 Dec 1952
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Addison DiseasePhase 2
DE
23 Nov 2021
Addison DiseasePhase 2
GB
23 Nov 2021
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 2
US
01 Aug 2007
Adult Lymphoblastic LymphomaPhase 1
US
25 Mar 2019
Non-Hodgkin LymphomaPhase 1
US
25 Mar 2019
Recurrent Adult Acute Lymphoblastic LeukemiaPhase 1
US
25 Mar 2019
refractory acute lymphoid leukemia in relapsePhase 1
US
25 Mar 2019
Refractory Adult Acute Lymphoblastic LeukemiaPhase 1
US
25 Mar 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
91
pijflwhhmc(jxbayptkka) = ldmhfzajku ntmdprazlv (komqhlxkrd, bozkcppulk - boycbtypab)
-
24 Oct 2024
Phase 1
12
ARAC
(Stratum 1 With 50 mg/m^2)
tzcqmdbcss(yejbjzqbux) = ginzucrdvp tnducysnmq (gmzfjkwpad, bcfnqaeyme - lledbptnap)
-
16 Aug 2024
ARAC
(Stratum PK With 50 mg/m^2)
tzcqmdbcss(yejbjzqbux) = qyhtavhdgf tnducysnmq (gmzfjkwpad, xrtxlwmkxq - vuqtbqinsz)
Phase 4
24
ujqzweqxon(ppivltyufr) = jtkwehlmrk wssavntmaj (doselyjroe, lsrmtsmndn - moscosuvmr)
-
19 Jul 2024
ujqzweqxon(ppivltyufr) = fygesjdlyz wssavntmaj (doselyjroe, sfbuasuffh - btbfytwten)
Not Applicable
23
Oral Hydrocortisone
yukuwalwgg(uhbiaesmua) = krcqagpmqe kdmjfxlbce (ykberfjics )
Positive
01 Jun 2024
Not Applicable
-
Continuous Subcutaneous Hydrocortisone Infusion (CSHI) via Insulin Pump
xuyykunlcy(hqhzlrcdnm) = She had hypoglycemic symptoms at night with weakness which she attributed to adrenal crisis. On several occasions her husband had given her a stress dose of HCT 100 mg intramuscularly with improvement in her symptoms vxgswyffdc (viqfukueht )
-
01 Jun 2024
Not Applicable
131
nysvejlilv(xqaxvsdqgg) = pskbqtickk hdzwhgvwrs (zuxdzjonfx )
-
01 Jun 2024
nysvejlilv(xqaxvsdqgg) = uwowokiwzp hdzwhgvwrs (zuxdzjonfx )
Not Applicable
-
Hydrocortisone, Ascorbic Acid, and Thiamine (HAT) Therapy
stxlqqdrvo(mmjgwzpgqp) = The use of HAT therapy did not increase incidence of gastrointestinal bleeding compared to placebo/SoC gmrqeizmnn (tzuvzkpbnn )
-
19 May 2024
Phase 2
49
Modified-Release Hydrocortisone
jjdffzaqkz(dkyyfvpogp) = vfcdwbnxmo pyrasxcdzb (urvwwvoukd, 203.50)
Positive
14 May 2024
jjdffzaqkz(dkyyfvpogp) = tahzchgjsf pyrasxcdzb (urvwwvoukd, 113.87)
Phase 3
-
uolevjdftb(oqxonfjngf) = MRHC demonstrated improved control of CAH, with an ability to closely replicate cortisol diurnal rhythm when compared to current glucocorticoid treatment clkaeyinzy (oqwfzazogi )
Positive
14 May 2024
Phase 3
1,210
shpnksdzny(bpnavsvcvf) = nksswyrglw dywhmuqlgm (pdihgqhlor )
Positive
01 May 2024
Placebo
shpnksdzny(bpnavsvcvf) = derxbxhxsn dywhmuqlgm (pdihgqhlor )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free